Development
Ekso Bionics Holdings, Inc.
EKSO
$3.14
-$0.11-3.39%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 36.50% | 38.39% | 35.73% | 60.58% | -12.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.50% | 38.39% | 35.73% | 60.58% | -12.88% |
| Cost of Revenue | 32.30% | 30.92% | 34.27% | 56.26% | 12.76% |
| Gross Profit | 41.18% | 45.67% | 37.36% | 65.43% | -30.52% |
| SG&A Expenses | -12.47% | -5.05% | 28.60% | 16.99% | -16.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.87% | 7.95% | 34.25% | 25.96% | -7.43% |
| Operating Income | 22.25% | 19.79% | -32.67% | -4.98% | 2.55% |
| Income Before Tax | -1.13% | 21.82% | -42.04% | 5.00% | -11.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.13% | 21.82% | -42.04% | 5.00% | -11.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.13% | 21.82% | -42.04% | 5.00% | -11.00% |
| EBIT | 22.25% | 19.79% | -32.67% | -4.98% | 2.55% |
| EBITDA | 33.60% | 25.75% | -33.99% | -0.70% | 3.09% |
| EPS Basic | 7.87% | 27.39% | -34.23% | 9.06% | -6.95% |
| Normalized Basic EPS | 7.82% | 27.41% | -34.19% | 9.08% | -6.95% |
| EPS Diluted | 6.29% | 27.39% | -34.23% | 9.06% | 5.77% |
| Normalized Diluted EPS | 7.82% | 27.41% | -34.19% | 9.08% | -6.95% |
| Average Basic Shares Outstanding | 9.77% | 7.67% | 5.84% | 4.46% | 3.80% |
| Average Diluted Shares Outstanding | 9.77% | 7.67% | 5.84% | 4.46% | 3.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |